402 related articles for article (PubMed ID: 17709369)
41. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J; Gavrilova O; Petzinger E
J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
[TBL] [Abstract][Full Text] [Related]
42. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
43. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
44. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
[TBL] [Abstract][Full Text] [Related]
45. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
Yamazaki M; Neway WE; Ohe T; Chen I; Rowe JF; Hochman JH; Chiba M; Lin JH
J Pharmacol Exp Ther; 2001 Mar; 296(3):723-35. PubMed ID: 11181899
[TBL] [Abstract][Full Text] [Related]
46. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
47. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.
Doran A; Obach RS; Smith BJ; Hosea NA; Becker S; Callegari E; Chen C; Chen X; Choo E; Cianfrogna J; Cox LM; Gibbs JP; Gibbs MA; Hatch H; Hop CE; Kasman IN; Laperle J; Liu J; Liu X; Logman M; Maclin D; Nedza FM; Nelson F; Olson E; Rahematpura S; Raunig D; Rogers S; Schmidt K; Spracklin DK; Szewc M; Troutman M; Tseng E; Tu M; Van Deusen JW; Venkatakrishnan K; Walens G; Wang EQ; Wong D; Yasgar AS; Zhang C
Drug Metab Dispos; 2005 Jan; 33(1):165-74. PubMed ID: 15502009
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
Mittapalli RK; Vaidhyanathan S; Dudek AZ; Elmquist WF
J Pharmacol Exp Ther; 2013 Mar; 344(3):655-64. PubMed ID: 23249624
[TBL] [Abstract][Full Text] [Related]
49. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
[TBL] [Abstract][Full Text] [Related]
50. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Lee LB; Pang J; Plise EG; Zhang X
Drug Metab Dispos; 2010 Sep; 38(9):1422-6. PubMed ID: 20522663
[TBL] [Abstract][Full Text] [Related]
51. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.
Katoh M; Suzuyama N; Takeuchi T; Yoshitomi S; Asahi S; Yokoi T
J Pharm Sci; 2006 Dec; 95(12):2673-83. PubMed ID: 16892207
[TBL] [Abstract][Full Text] [Related]
52. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
[TBL] [Abstract][Full Text] [Related]
53. P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.
Lagas JS; Sparidans RW; van Waterschoot RA; Wagenaar E; Beijnen JH; Schinkel AH
Antimicrob Agents Chemother; 2008 Mar; 52(3):1034-9. PubMed ID: 18195061
[TBL] [Abstract][Full Text] [Related]
54. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
55. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
[TBL] [Abstract][Full Text] [Related]
56. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
Pharm Res; 2007 Sep; 24(9):1720-8. PubMed ID: 17380257
[TBL] [Abstract][Full Text] [Related]
57. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
Ejsing TB; Pedersen AD; Linnet K
Hum Psychopharmacol; 2005 Oct; 20(7):493-500. PubMed ID: 16118767
[TBL] [Abstract][Full Text] [Related]
58. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Wortelboer HM; Usta M; van der Velde AE; Boersma MG; Spenkelink B; van Zanden JJ; Rietjens IM; van Bladeren PJ; Cnubben NH
Chem Res Toxicol; 2003 Dec; 16(12):1642-51. PubMed ID: 14680379
[TBL] [Abstract][Full Text] [Related]
59. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
60. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
